
|Articles|February 1, 2007
Broad-spectrum agent may be option for resistant UTIs
San Francisco-Community-acquired urinary tract infections are becoming increasingly difficult to treat in several countries due to the widespread increase in drug resistance. In Spain, isolated strains of Escherichia coli have become resistant to nearly all oral antimicrobials, reported Genoveva Yague III, MD, professor of microbiology at the University of Murcia Medical School, Murcia, Spain.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5










